RBC Capital analyst Luca Issi maintained a Buy rating on Caribou Biosciences (CRBU – Research Report) yesterday and set a price target of $19.00. The company’s shares closed yesterday at $7.22.
According to TipRanks, Issi is an analyst with an average return of -18.3% and a 28.73% success rate. Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ionis Pharmaceuticals, and uniQure.
Currently, the analyst consensus on Caribou Biosciences is a Strong Buy with an average price target of $22.60.
See Insiders’ Hot Stocks on TipRanks >>
CRBU market cap is currently $656.2M and has a P/E ratio of -4.81.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRBU in relation to earlier this year. Last month, Steven Kanner, the CSO of CRBU bought 30,577.00 shares for a total of $82,252.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caribou Biosciences (CRBU) Company Description:
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
Read More on CRBU:
